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Abstract.
A sensitive and reproducible enzyme-linked immunosorbent assay (ELISA) for the determination of the concentration of ivermectin (IVM) in biological fluids was developed. A conjugate of IVM on bovine serum albumin and poly-L-lysine was used to produce antibodies in rabbits and served as a solid-phase marker for titration of antibodies, respectively. The competitive ELISA was conducted by simultaneously incubating IVM and IVM-biotin conjugate with anti-IVM antiserum over goat anti-rabbit IgG (Fc) and then determining the amount of bound IVM biotin with avidin-peroxidase conjugate as a tracer. The coefficient of variation for the assay was less than 10% in the range of 0.3â€"10 ng/ml. The limit of detection was 0. 1 ng/ml. The cross-reactivities of anti-IVM antiserum with some anthelmintic drugs were negligible. Using this ELISA, serum levels of IVM were easily determined in Mon golian jirds (Meriones unguiculatus) up to 72 hr following a single oral dose of 500 p@g/kgof body weight.
Ivermectin (WM), a macrocyclic lactone produced by an actinomycetes, Streptomyces avermitilis, is a potent new an tiparasitic agent. It is active at extremely low doses against a wide variety of nematode and arthropod parasites.' Re cently, its antiparasitic potency against Onchocerca volvulus,
Wuchereria bancrofti, and Brugia malayi has been tested in
humans.2 Both in terms of clinical efficacy and side effects, NM is becoming a microfilaricidal agent of first choice.2 As a prerequisite for studying the pharmacokinetics of IVM in humans, a method is needed for IVM analysis that is suffi ciently sensitive to determine the concentration of IVM in biological fluids. Several high-performance liquid chroma tography (HPLC) procedures have been reported for deter mining IVM in plasma.@7 However, HPLC procedures ne cessitate time-consuming extractions and require a relatively large amount of blood, and thus are unsuitable for the routine screening of large numbers of samples or field use. Recently, Schmidt and others have produced monoclonal antibodies to IVM and developed an enzyme immunoassay as an alter native to HPLC for detecting IVM in agricultural and en vironmental samples.8 However, their assay system was not applied to the measurement of IVM in biological fluids of animals. We have investigated this approach further with the intent of devising a simple, sensitive enzyme-linked immu nosorbent assay (ELISA) for detection of IVM in the blood of humans and animals. In this report, we describe 1) the production of anti-IVM antibodies in the rabbit, 2) the de velopment of a competitive ELISA, and 3) the preliminary application of this immunoassay to the study of the phar macokinetics of IVM in Mongolian jirds (Meriones ungui culatus). MATERIALS 
AND METHODS

Materials
Preparation
of IVM-BSA conjugate used as an im munogen. The IVM was first converted to the nitrophenyl compound and conjugated with BSA as shown in Figure 1 . Ivermectin (74 mg), triethylamine (34 mg), and 4-diethyl aminopyridine (34 mg) were dissolved in 2 ml of methylene chloride and cooled to 4Â°C,then 4-nitrophenyl chloroformate (35 mg) dissolved in 0.5 mi of methylene chloride was added and stirred for 1 hr at 4Â°C. Two milliliters of water was added to the above solution. The solution was extracted with ether, the extract was washed three times with water and dried over anhydrous sodium sulfate, the solvent was re moved under vacuum, and the residue was purified by pre parative thin-layer chromatography (TLC, silica gel 60F254, 20 x 20 cm with a thickness of 0.5 mm; E. Merck, Darm stadt, Germany) with tetrahydrofuran:chloroform
(1 : 10) to obtain the nitrophenyl. compound (42 mg, 48% yield). The nitrophenyl compound (12 mg) was dissolved in 0.5 ml pyr idine and slowly added to a solution of BSA (25 mg) dis and N-hydroxysuccinimide (1 mg) were added to the solu tion of IVM oxime (5 mg) dissolved in 0.2 ml of dimethyl formamide (DMF), and then stirred for 30 mm at room tem perature. This solution was slowly added to poly-L-lysine hydrobromide (5 mg) dissolved in 0.25 ml of 0. 13 M NaHCO3 and stirred for 1.5 hr at room temperature.
The resulting conjugate was dialyzed against 3 liters of 0. 1 M NaHCO3 for two days. The solution of conjugate was ad justed to pH 5.5 with 1 N HC1 and centrifuged at 2,500 rpm for 30 mm. The supernate was used as a solid-phase marker.
Preparation of IVM-blotin conjugate. The IVM-biotin conjugate was prepared using an N-hydroxysuccinintide es
Solid-phase marker (IVM-BSA) conjugate used as the immunogen and NM-poly-L-lysine ten method of Liu and others ( Figure 2 ). â€ẫ€Ĩ vermectin oxime (1.5 mg), N-hydroxysuccinintide (0.2 mg), and dicyclohexyl carbodiimide (0.35 mg) were dissolved in 50 pA of DMF and incubated for 1 hr at room temperature.
The mixture was added to a solution of N-(2-aminoethyl)biotinamide (0.7 mg) and triethylamin (3 pA) in 200 p.1 of DMF, stirred for two days at room temperature, and applied to a preparative TLC plate. The plate was developed in chloroform-methanol (3: 1). The IVM-biotin conjugate had an Rf value of 0.58 and was dissolved in 1 ml of DMF and stored at â€"30Â°C (stock IVM-biotin solution).
Immunization. A rabbit was injected both intradermally and intramuscularly with the IVM-BSA conjugate (I mg) dissolved in 1 ml of saline and emulsified with 1 ml of Freund's complete adjuvant at sites on a shaved back area. For booster injection, the IVM-BSA conjugate (0.5 mg) in 0.5 ml of saline and 0.5 ml of Freund's incomplete adjuvant was used. The repeated boosters were given on weeks 2, 4, salt, 5.0 mM H2O2, 300 mM citric acid, and 51 mM disodium hydrogen phosphate per liter was added, and the color was allowed to develop in the dark for 40 mm at room temperature. One hundred microl iters of sodium azide (1 g/L in distilled water) was added to terminate the enzymatic reaction, and absorbances were measured at 405 nm with a microplate reader (MultiskanÂ® BICHROMATIC;
Labsystems, Helsinki, Finland).
Detennination of IVM concentrations in biological flu
ids from a standard curve. A standard curve was con structed in every experiment in a range of 0.03â€"30 ng/mi. It showed the percent maximal absorbance on the y-axis and the concentration of DIM on the x-axis. When the percent absorbance of sample to be tested was within the working range of the standard curve, the concentration of IVM in the sample was determined.
Determination of serum concentrations of IVM in jirds. Ivermectin was diluted 1:100 in ethanol:saline (1:3 [v/ v]). Four male jirds weighing 104â€"106 g were given a single oral dose of NM at 500 p@g/kgof body weight. Blood from the retro-orbital sinus (20 pA) was collected into tubes at 0, The assay precision was examined at five different NM levels over the range 0.1â€"10ng/ml ( Table  2 ). The recoveries of NM added were satisfactory, and the coefficient of within assay variation was low. Therefore, the detection limit of the competitive ELISA using IVM-biotin and avidin-peroxidase conjugate is 0.1 ng/mi. Application of the method to biological samples. The present enzyme immunoassay was applied to monitor the serum concentration of NM after a single oral dose (500 @.Lg/kg of body weight) to male jirds. Figure 4 shows the mean serum concentration-time profile of NM after admin istration. The maximum serum concentration of 43.8 ng/ml was attained 2 hr after administration.
Thereafter, the serum level rapidly decreased, but interestingly, it again showed the high value 24 hr after administration.
DISCUSSION
Ivermectin-protein
conjugates have been formed and used as immunizing and screening antigen for the determination of IVM in biological fluids. 8 We report here the successful preparation of NM-BSA conjugates and production of an tibodies to NM in the rabbit. The immunogenicity of NM protein conjugates and the specificity of an antiserum for NM are markedly influenced by the sites of the NM mol ecule that are derivatized to couple with the carrier protein.
In our study, the site of coupling of NM with BSA was not defined exactly. However, the most probable site of coupling is at the C-S position because the hydroxyl group of the allylic position is generally more reactive than the hydroxyl group at the Câ€•-4position. fuged at 2,000 rpm for 15 mm. The serum was separated and stored at â€"30Â°C until assayed. The pooled normal jird serum diluted 1:100 in phosphate buffer-BSA containing various concentrations of IVM was used for the construction of a standard curve for the determination of the NM con centration in jird serum. The serum samples to be measured were first diluted 1: 100 in phosphate buffer-BSA, and the concentration of IVM in the samples was then measured by the competitive ELISA using IVM-biotin.
RESULTS
Production of antibodies against IVM. An indirect ELI
SA was used to monitor the production of IVM antibodies in the rabbit. The serum samples taken at 6â€"12weeks had a titer greater than 10,000. The highest titer was detected at week 8. Repeated booster injections after week 8 did not significantly increase IVM titers. Therefore, in the subse quent experiments, serum samples taken eight weeks after the initial immunization were used.
Competitive indirect ELISA using IgG-peroxidase con jugate. A typical IVM competitive ELISA dose-response curve is shown in Figure 3 . The dose response range for this curve is between 10 and 1,000 ng/ml. Competitive ELISA using IVM-biotin and avidin-per oxidase conjugate. A typical IVM competitive ELISA dose response curve is shown in Figure 3 . The dose-response range for this curve is between 0. 1 and 10 ng/ml. The sen sitivity of the competitive ELISA using the IVM-biotin and avidin-peroxidase conjugates is 100 times as high as that of the ELISA using the IgG-peroxidase conjugate. Therefore, in subsequent experiments, the competitive ELISA was per Recently, a Brugia pahangi-jird model has been widely used for primary screening of anti-filarial drugs.2 However, no pharmacokinetic study of NM in jirds has been done. Therefore, we attempted to measure NM concentration in these animals. Our method successfully determined the se rum concentration-time profiles of IVM in jirds up to 72 hr after administration of NM. The serum concentration-time profiles of our pilot study, however, are different from those reported by Schnitzerling and Nolan,3 Kojima and Yama moto,4 and Krishna and Klotz.@ They reported a monoex ponential decrease in the plasma level of IVM following the peak concentrations in cows, dogs, and humans.
There are three possible explanations for the appearance of two peaks after oral administration of NM to jirds. First, NM is in soluble in water. Therefore, there was considerable variation in the absorption of NM in the intestine of the jirds. If this was the case, the individual variation in the peak time after oral administration should be more prominent. Second, NM is metabolized to products that influence the assay system. This is also very unlikely because the anti-NM antibodies we used are relatively specific for IVM and NM is reported to be excreted mainly in the feces in an unchanged form.' Third, IVM undergoes enterohepatic circulation (EHC). Drugs that undergo EHC, e.g., the steroids, show two peaks in the serum concentration-time profiles that are similar to the two peaks observed in this study.'3 Interestingly, EHC of NM in the salmon has been reported,'4 and Edwards and others reported that IVM was excreted into the bile in mice.'5 Thus, the third explanation is not unlikely. Further studies will be needed to explain the appearance of two peaks in concentration-time profile of NM in jirds. The concentration of IVM in the blood has been deter mined by HPLC. However, HPLC procedures are time-con suming, require large amounts of blood, and are unsuitable for routine screening of large numbers of samples or field use. We have developed a simple, sensitive, and reproducible competitive ELISA for the determination of NM in biolog ical fluids. Our method requires only 5 pA of serum for trip licate determinations with a detection limit of 10 ng/ml in serum. This assay can be used for monitoring plasma levels of IVM in clinical studies for evaluating its optimal dosage regimen and pharmacokinetics of IVM in humans and cx perimental animals. The IVM oxime-poly-L-lysine conjugate as a solid-phase marker was prepared by the use of carbomethoxyloxime as a cross-linker in consideration of the fact it might avoid a cross-reaction with the antibody produced against the im munogen linkage group of carboxycarbonyl.
We tested a classical competitive ELISA using anti-IVM antibodies and IVM-poly-L-lysine conjugate as a solid phase marker. The detection limit of this assay was 10 ng/ml in the buffer sys tem used. To develop a more sensitive enzyme immunoassay for IVM, we investigated some other configurations includ ing NM-biotin.
Among them, the configuration using NM biotin and avidin peroxidase gave the highest sensitivity (0.1 ng/ml in buffer). This assay probably enables NM and NM-biotin to compete successfully for antibody due to the small molecular weight of biotin. It is also possible that the enzyme reaction is amplified by biotin-avidin system due to high-affinity binding between biotin and avidin. The detec tion limit of our method is 5â€"10-fold lower than those of the HPLC procedures@7 and that of a competitive enzyme im munoassay using monoclonal antibody to NM.8
The cross-reactivity of the NM antibodies with some ant helminthic drugs was negligible. Recently, it had been con fidently expected that the combination of NM and diethyl carbamazine (DEC) would be effective for the treatment of lymphatic filariasis.'2 Our competitive ELISA will be useful for the evaluation of the efficacy of the combination of NM and DEC.
The competitive ELISA we describe here was usable for the accurate detection of IVM in serum without interference from endogenous or exogenous substances in rodents blood when the serum sample was diluted 1:100 in buffer. By di rect dilution of serum in assay buffer, our assay can detect concentration as little as 10 ng/mi of IVM in 2â€"5-p.lserum samples. The actual detection limit in serum was 100 times higher than that in buffer because of the dilution factor of 20 40 60
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